Phase II trial of extended-dosing temozolomide in patients with melanoma
Petra Rietschel(Memorial Sloan Kettering Cancer Center), P. B. Chapman(Memorial Sloan Kettering Cancer Center), Jedd Wolchok(Memorial Sloan Kettering Cancer Center), Katy Smith(Memorial Sloan Kettering Cancer Center), KJ Busam(Memorial Sloan Kettering Cancer Center), Susan E. Krown(Memorial Sloan Kettering Cancer Center), Scott R. Gerst(Memorial Sloan Kettering Cancer Center), Samuel Ejadi(Memorial Sloan Kettering Cancer Center), A. Jungbluth(Memorial Sloan Kettering Cancer Center), Katherine S. Panageas(Mayo Clinic)
Cited by 0
Related Papers
How To Build and Interpret a Nomogram for Cancer Prognosis
|Journal of Clinical Oncology|2008|3.4k
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
|Journal of Clinical Oncology|2015|1.1k
Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma
|Journal of Clinical Oncology|1999|763
Kaposi sarcoma
|Nature Reviews Disease Primers|2019|707
Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and Lipodystrophy
|Clinical Infectious Diseases|2001|680